Christopher Reed’s Story

Christopher Reed headshot

J. Christopher Reed

Lupus Foundation of America-Georgia

Support Group Facilitator, Advocacy Chair

Christopher was diagnosed with lupus in 1990 at the age of 16. Lupus attacked his heart, lungs, kidneys, digestive system, veins, and nervous system. Christopher’s lupus journey began with chronic headaches and frequent muscle spasms then progressed to frequent fevers, arthritis, and tremendous weight loss. He was barely able wrap his hands around the steering wheels during driver’s ed class and walking up the stairwell to his bedroom felt like he was having a heart attack. In 2004, he developed stage 3 kidney disease.  With his first job out of law school, Christopher was juggling kidney disease and horrible chemotherapy treatments. In 2018, he almost lost his life due to septic shock.

Overtime, Christopher continued to suffer from severe organ involvement. He was constantly worried about a lack of insurance and the cost of his life-saving medication.

Despite these serious lupus attacks, and moving back to his parent’s home, Christopher earned a bachelor’s degree with honors from the Georgia State University and a law degree from Tulane University. He attributes his success to God, the support of family and the support received at an early age from the Lupus Foundation of America, Georgia Chapter (LFAGA).

In speaking with Christopher, one can tell he is an avid advocate passionate about tackling healthcare policy and increasing lupus research. He previously chaired the Georgia Council on Lupus Education and Awareness (Council), a sponsored entity created by the state legislature to improve the lives of Georgians living with lupus.  He has worked to establish the Georgia Lupus Collaborative, an advisory group and think tank charged with improving the lives of people with lupus in Georgia.

Christopher currently serves as a Support Group Facilitator, Advocacy Chair, and Project Manager for the Lupus Foundation of America-Georgia Chapter. His support group is specifically designed for men. As Advocacy Chair, he gives presentations on patient advocacy and public health policy as well as being a writer on Lupus. Each year, over a one hundred lupus advocates engage in Lupus Day at the Georgia State Capitol. He remains involved in Health Research and serves to increase African American participation in clinical trials through a series of education sessions, open discussion, and dialogues with African American physicians and African American researchers.

Christopher has been honored to be a recipient of several awards including the Mary Cann Achievement Award from the Lupus Foundation of America, Georgia Chapter.

The post Christopher Reed’s Story appeared first on Georgia Bio.

March 24, 2026
Georgia Life Sciences is proud to be featured in the latest issue of Inside Medicine Magazine – Atlanta, highlighting the continued growth and impact of Georgia’s life sciences ecosystem.This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. We’re proud to help showcase the people and organizations advancing healthcare across our region and beyond. Read our feature here: https://hubs.la/Q04876WJ0
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
MORE POSTS